1549812-20-5

Basic information

• Product Name: Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate
• Synonyms: Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate;3-Methoxy-4-methylamino-5-nitro-benzoic acid methyl ester
• CAS NO: 1549812-20-5
• Molecular Formula: C₁₀H₁₂N₂O₅
• Molecular Weight: 240.21268
• EINECS: -0
• Mol File: 1549812-20-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate(1549812-20-5)
• EPA Substance Registry System: Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate(1549812-20-5)

Safety Data

• Hazardous Substances Data: 1549812-20-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique functional groups allow for versatile reactions and the formation of a wide range of products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate is used as a research compound for the development of new drugs. Its structural features may contribute to the discovery of novel therapeutic agents with potential medicinal properties.
Used as an Intermediate in Chemical Production:
Methyl 3-methoxy-4-(methylamino)-5-nitrobenzoate may also serve as an intermediate in the production of other chemicals, where its functional groups can be further modified or utilized in the synthesis of target compounds.

Upstream product

• 63603-09-8 methyl 4-chloro-3-methoxy-5-nitrobenzoate 
• 593-51-1 methylamine hydrochloride 
• 42590-00-1 4-hydroxy-3-methoxy-5-nitrobenzoic acid methyl ester 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 74-89-5 methylamine 

Downstream Products

• 1549812-23-8 3-methoxy-4-(methylamino)-5-nitrobenzoic acid 
• 1549812-25-0 (R)-(1-(3-methoxy-4-(methylamino)-5-nitrobenzoyl)piperidin-3-yl)carbamic acid tert-butyl ester 

Relevant articles and documents

ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME

The present disclosure provides compounds that are ACSS2 inhibitors. In certain embodiments, the compounds of the disclosure are useful for treating and/or preventing certain types of cancer.

Peptidylarginine deiminase inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a peptidylarginine deiminase PAD4 inhibitor compound shown in a formula (I) or pharmaceutically acceptable salts,stereoisomers and tautomers thereof, as well as pharmaceutical compositions, pharmaceutical preparations and application thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are as defined in the specification. The compound has inhibitory effect on peptidylarginine deiminase PAD4, and can be used for treating various diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

COVALENT INHIBITORS OF PAD4

The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

BICYCLIC INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

HETEROARYL INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS

Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I): wherein; R1 is hydrogen or C1-6alkyl;R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy;R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl;R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6 alkyl;A is C—R5 or N;B is C—R6 or N;D is C—R7 or N;with the proviso that at least one of A, B, and D, is N;R5 is hydrogen or C1-6alkyl;R6 is hydrogen or C1-6alkyl;R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy;R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen;R9 is hydrogen or hydroxy;R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS

Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O-, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.